Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Observer-Blinded, Phase 3 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

Next Previous
X
Search
Trial Profile

A Randomized, Observer-Blinded, Phase 3 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-19 vaccine adjuvanted Novavax (Primary)
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics
  • Acronyms Lot Consistency; Study 307
  • Sponsors Novavax

    • Most Recent Events

    • 29 Aug 2023 Primary endpoint (Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMEUs [ Time Frame: Day 29 ]) has been met according to results published in vaccine.
    • 29 Aug 2023 Results assessing whether NVX-CoV2373 would induce robust responses when used as a booster published in the Vaccine.
    • 12 Oct 2022 Results presented in a Novavax media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top